Advancing discovery through Alluvi research

Alluvi Retatrutide is an investigational medication designed for weight management and metabolic health. It belongs to a new class of drugs called triple agonists, targeting GLP-1, GIP, and glucagon receptors. This unique mechanism helps regulate appetite, improve blood sugar control, and promote fat loss more effectively than single-pathway treatments. Early clinical studies suggest Alluvi Retatrutide may offer significant weight reduction, improved insulin sensitivity, and cardiovascular benefits. It is being evaluated for obesity, type 2 diabetes, and related conditions. While results are promising, Alluvi Retatrutide is not yet widely available, pending further research and regulatory approval to confirm its safety and effectiveness.